InsidersTradesSigma
Plus Therapeutics, INC. Stock: price and insider trades · United States · SEC (Form 4)
Track the Plus Therapeutics, INC. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Plus Therapeutics, INC. has published 46 reports. Market capitalisation: €27m. The latest transaction was disclosed on 1 July 2026 (Levée d'options). Among the most active insiders: HEDRICK MARC H. All data is accessible without an account.
46
Insider Decl.
0
Thresholds
€333,455
42 ops.
Buy Volume
€4,158
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Plus Therapeutics, INC. Strong Buy (bullish), based on 4 analysts. Average price target: US$36.00.
59Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations46 total
922 sharesCommon StockSEC:0001193125-26-292654:0
922 sharesCommon StockSEC:0001193125-26-292639:0
4,000 shares@ US$1.49923.2% of flowCommon StockSEC:0000950170-24-107008:0
Ideal exit: 10 Jun 2025 (T+270)
6,285 shares@ US$1.354332.9% of flowCommon StockSEC:0000950170-24-106605:0
Ideal exit: 9 Jun 2025 (T+270)
5,000 shares@ US$1.336211.2% of flowCommon StockSEC:0000950170-24-106179:0
Ideal exit: 8 Jun 2025 (T+270)
12,500 shares@ US$1.3512.5% of flowCommon StockSEC:0000950170-24-106180:0
Ideal exit: 8 Jun 2025 (T+270)
8,000 shares@ US$1.229915.1% of flowCommon StockSEC:0000950170-24-105331:0
Ideal exit: 7 Jun 2025 (T+270)
4,098 shares@ US$1.2714.0% of flowCommon StockSEC:0000950170-24-105330:0
Ideal exit: 7 Jun 2025 (T+270)
4,902 shares@ US$2.0439.9% of flowCommon StockSEC:0000950170-24-057453:0
Ideal exit: 2 Feb 2025 (T+270)
12,255 shares@ US$2.0439.3% of flowCommon StockSEC:0000950170-24-057455:0
Ideal exit: 2 Feb 2025 (T+270)
4,167 shares@ US$2.0417.8% of flowCommon StockSEC:0000950170-24-057451:0
Ideal exit: 2 Feb 2025 (T+270)
12,255 shares@ US$2.0418.9% of flowCommon StockSEC:0000950170-24-057454:0
Ideal exit: 2 Feb 2025 (T+270)
4,902 shares@ US$2.0427.6% of flowCommon StockSEC:0000950170-24-057456:0
Ideal exit: 2 Feb 2025 (T+270)
9,804 shares@ US$2.0434.5% of flowCommon StockSEC:0000950170-24-057452:0
Ideal exit: 2 Feb 2025 (T+270)
2,068 shares@ US$1.95976.3% of flowCommon StockSEC:0001209191-23-058816:0
1,000 shares@ US$1.773.7% of flowCommon StockSEC:0001209191-23-055638:0
Ideal exit: 11 Aug 2024 (T+270)
2,000 shares@ US$1.456.1% of flowCommon StockSEC:0001209191-23-055264:0
Ideal exit: 6 Aug 2024 (T+270)
5,000 shares@ US$1.6517.4% of flowCommon StockSEC:0001209191-23-054914:0
Ideal exit: 4 Aug 2024 (T+270)
1,395 shares@ US$1.504.4% of flowCommon StockSEC:0001209191-23-054650:0
Ideal exit: 2 Aug 2024 (T+270)
6,993 shares@ US$1.433131.9% of flowCommon StockSEC:0001209191-23-049535:0
Ideal exit: 9 Jun 2024 (T+270)
20,000 shares@ US$1.703125.8% of flowCommon StockSEC:0001209191-23-049058:0
Ideal exit: 7 Jun 2024 (T+270)
1,000 shares@ US$3.986.9% of flowCommon StockSEC:0001209191-23-035267:0
Ideal exit: 2 Mar 2024 (T+270)
2,500 shares@ US$3.640615.2% of flowCommon StockSEC:0001209191-23-027213:0
Ideal exit: 28 Jan 2024 (T+270)
1 shares@ US$1,000.004.0% of flowSeries F Preferred StockSEC:0001209191-23-016526:0
Ideal exit: 28 Nov 2023 (T+270)
1,500 shares@ US$0.31471.0% of flowCommon StockSEC:0001209191-23-001447:0
25 of 46 declarations
About Plus Therapeutics, INC.
Plus Therapeutics, Inc. (ticker: PSTV) is a U.S.-based biotechnology company listed on the Nasdaq Capital Market in the United States. It is focused on precision oncology, with a clinical-stage platform centered on targeted radiotherapeutics and diagnostics for cancers of the central nervous system (CNS), particularly hard-to-treat and rare disease settings. The company is headquartered in Houston, Texas, and operates with additional laboratory and clean-room capabilities in Texas, giving it a hybrid development model that combines research, preclinical work, manufacturing support, and proximity to leading cancer institutions. ([plustherapeutics.com](https://plustherapeutics.com/about-us/?utm_source=openai)) The company traces its roots back to 1996, but its current identity reflects a strategic shift toward radiopharmaceutical oncology. Over time, Plus Therapeutics has repositioned its portfolio around rhodium? No—around rhenium-based therapeutics and advanced delivery technologies, including nanoliposomal formulations and radioisotope-loading approaches designed to deliver local beta radiation while limiting off-target exposure. This evolution has made the business more focused and more specialized, with a clear emphasis on translating targeted radiation science into clinically relevant cancer therapies. ([stockanalysis.com](https://stockanalysis.com/stocks/pstv/company/?utm_source=openai)) At the center of the portfolio is REYOBIQ™, the company’s lead program for CNS cancers such as leptomeningeal metastases (LM) and recurrent glioblastoma (GBM). In parallel, Plus Therapeutics is building out CNSide Diagnostics through its wholly owned subsidiary CNSide Diagnostics, aiming to support more precise detection and monitoring in CNS cancer care. The company’s business model therefore spans both therapeutics and diagnostics, which is strategically relevant in oncology settings where treatment selection and disease monitoring can materially affect outcomes. ([ir.plustherapeutics.com](https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-provides-business-update-cnside-diagnostics/?utm_source=openai)) From a competitive standpoint, Plus Therapeutics occupies a niche position in a highly specialized corner of oncology. It does not compete broadly as a large-cap pharmaceutical company; instead, it aims to differentiate through a targeted radiotherapeutic platform for underserved cancers where clinical need remains high. Its competitive strengths lie in its focus, its proprietary formulation know-how, and its ability to combine image-guided local radiation delivery with manufacturing partnerships that support scale-up. The company has expanded collaboration with third-party radiopharmaceutical manufacturers such as SpectronRx and Telix IsoTherapeutics to secure supply of rhenium-186 and improve development redundancy. ([ir.plustherapeutics.com](https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-and-spectronrx-announce-radiotherapeutic?utm_source=openai)) Recent milestones have included the release of full-year 2025 results in March 2026, along with updates on near-term clinical and commercial objectives for REYOBIQ and CNSide. During 2025, the company also reported improved Nasdaq compliance on stockholders’ equity and continued to pursue funding and operational initiatives to support late-stage development. For investors, Plus Therapeutics remains a high-risk, catalyst-driven micro-cap biotech story whose value proposition depends on execution in clinical development, regulatory progress, and industrial scale-up. ([nasdaq.com](https://www.nasdaq.com/press-release/plus-therapeutics-reports-2025-results-business-progress-and-2026-anticipated?utm_source=openai))
